NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21) Department of Health and Human Services National Institutes of Health
The purpose of this funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), is to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research in all areas relevant to the mission of the NCI. By using the R21 mechanism, this FOA will support exploratory/developmental projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, and/or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).
Applications for R21 awards should describe projects distinct from those supported through the traditional R01 mechanism. For example, such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Another example could include the unique and innovative use of an existing methodology to explore a new scientific area. Conversely, long-term projects, or projects designed to increase knowledge in a well-established area, should not be submitted as R21 applications.
Applications submitted under this mechanism should break new ground or extend previous discoveries toward new directions or applications. Projects of limited cost or scope that use widely accepted approaches and methods within well-established fields are better suited for the R03 small grant mechanism, which is presently also supported by the NCI Omnibus R03 FOA,PAR-14-007.
All areas of cancer research relevant to the mission of the NCI are appropriate for projects submitted to this FOA (for a list of extramural research funding programs at the NCI, go tohttp://www.cancer.gov/researchandfunding/extramural). Proposed projects may involve basic, translational, clinical, and/or population research. Examples of relevant areas include but are not limited to studies of: cancer biology; cancer control; cancer diagnosis; cancer disparities; cancer prevention; and cancer treatment.
|Posted Date:||Sep 1, 2015|
|Creation Date:||Sep 1, 2015|
|Original Closing Date for Applications:||Nov 10, 2015|
|Current Closing Date for Applications:||Nov 10, 2015|
|Archive Date:||Dec 11, 2015|
|Estimated Total Program Funding:|
City or township governments
Special district governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public and State controlled institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
For profit organizations other than small businesses
Private institutions of higher education
Native American tribal governments (Federally recognized)
Independent school districts
|Additional Information on Eligibility:||Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.|
|Agency Name:||National Institutes of Health|
|Description:||The National Cancer Institute (NCI) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in all areas of cancer research. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).|
|Link to Additional Information:||http://grants.nih.gov/grants/guide/pa-files/PAR-15-340.html|